FEN1 and cancer: In summary, we have presented evidence of combination potential, ranging from additivity to strong synergy, with a variety of DDRi. In vitro efficacy has been observed independent of HR status, opening up the scope of both FEN1 inhibitors and putative combination partner DDRi beyond HRD cancers.